PacBio Q4 revenue rises 14% driven by strong consumable sales

Reuters

02/13

PacBio Q4 revenue rises 14% driven by strong consumable sales

Overview

Life science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable sales
Adjusted net income for Q4 beat analyst expectations
Company completed sale of short-read sequencing assets, strengthening balance sheet

Outlook

Company plans to launch SPRQ-Nx to lower sequencing costs in 2026
PacBio aims to drive growth with strengthened balance sheet post asset sale
Company did not provide specific financial guidance for 2026

Result Drivers

RECORD CONSUMABLE SALES - Consumable revenue reached an all-time high, contributing significantly to Q4 revenue growth
ASSET SALE - Completed sale of short-read sequencing assets, strengthening balance sheet
DECLINE IN REVIO PLACEMENTS - Revio system placements decreased compared to the previous year

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Adjusted Net Income	Beat	-$37.60 mln	-$44.30 mln (4 Analysts)
Q4 Adjusted Gross Profit		$17.80 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, about 8.7% above its February 11 closing price of $1.84

Press Release: ID:nGNX8cG9QQ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2611557908"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611557908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611557908?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 05:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611557908","market":"fut","top_or_hot":-1,"title":"PacBio Q4 revenue rises 14% driven by strong consumable sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>PacBio Q4 revenue rises 14% driven by strong consumable sales</title></head><body><p><span>Overview</span></p><ul><li><p>Life science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable sales</p></li><li><p>Adjusted net income for Q4 beat analyst expectations</p></li><li><p>Company completed sale of short-read sequencing assets, strengthening balance sheet</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to launch SPRQ-Nx to lower sequencing costs in 2026</p></li><li><p>PacBio aims to drive growth with strengthened balance sheet post asset sale</p></li><li><p>Company did not provide specific financial guidance for 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>RECORD CONSUMABLE SALES - Consumable revenue reached an all-time high, contributing significantly to Q4 revenue growth</p></li><li><p>ASSET SALE - Completed sale of short-read sequencing assets, strengthening balance sheet</p></li><li><p>DECLINE IN REVIO PLACEMENTS - Revio system placements decreased compared to the previous year</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$37.60 mln</p></td><td><p>-$44.30 mln (4 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted Gross Profit</p></td><td></td><td><p>$17.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 6 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, about 8.7% above its February 11 closing price of $1.84</p></li></ul><p>Press Release: <span>ID:nGNX8cG9QQ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PacBio Q4 revenue rises 14% driven by strong consumable sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacBio Q4 revenue rises 14% driven by strong consumable sales\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-13 05:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>PacBio Q4 revenue rises 14% driven by strong consumable sales</title></head><body><p><span>Overview</span></p><ul><li><p>Life science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable sales</p></li><li><p>Adjusted net income for Q4 beat analyst expectations</p></li><li><p>Company completed sale of short-read sequencing assets, strengthening balance sheet</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to launch SPRQ-Nx to lower sequencing costs in 2026</p></li><li><p>PacBio aims to drive growth with strengthened balance sheet post asset sale</p></li><li><p>Company did not provide specific financial guidance for 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>RECORD CONSUMABLE SALES - Consumable revenue reached an all-time high, contributing significantly to Q4 revenue growth</p></li><li><p>ASSET SALE - Completed sale of short-read sequencing assets, strengthening balance sheet</p></li><li><p>DECLINE IN REVIO PLACEMENTS - Revio system placements decreased compared to the previous year</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$37.60 mln</p></td><td><p>-$44.30 mln (4 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted Gross Profit</p></td><td></td><td><p>$17.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 6 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, about 8.7% above its February 11 closing price of $1.84</p></li></ul><p>Press Release: <span>ID:nGNX8cG9QQ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMI","symbol_name":"康明斯","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z81GE:1","article_id":"2611557908","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611557908","pubTimestamp":1770931652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PacBio Q4 revenue rises 14% driven by strong consumable salesOverviewLife science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable salesAdjusted net income for Q4 beat analyst expect","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMI":"康明斯","PACB":"Pacific Biosciences of Californi","BK4121":"生命科学工具和服务","BK4149":"建筑机械与重型卡车","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","BK4567":"ESG概念","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4588":"碎股","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC"},"translate_title":"受耗材销售强劲推动，PacBio第四季度收入增长14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMI":0.9,"PACB":0.9},"content_text":"PacBio Q4 revenue rises 14% driven by strong consumable salesOverviewLife science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable salesAdjusted net income for Q4 beat analyst expectationsCompany completed sale of short-read sequencing assets, strengthening balance sheetOutlookCompany plans to launch SPRQ-Nx to lower sequencing costs in 2026PacBio aims to drive growth with strengthened balance sheet post asset saleCompany did not provide specific financial guidance for 2026Result DriversRECORD CONSUMABLE SALES - Consumable revenue reached an all-time high, contributing significantly to Q4 revenue growthASSET SALE - Completed sale of short-read sequencing assets, strengthening balance sheetDECLINE IN REVIO PLACEMENTS - Revio system placements decreased compared to the previous yearKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Adjusted Net IncomeBeat-$37.60 mln-$44.30 mln (4 Analysts)Q4 Adjusted Gross Profit$17.80 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 6 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy.\"Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, about 8.7% above its February 11 closing price of $1.84Press Release: ID:nGNX8cG9QQFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}